Results 81 to 90 of about 590 (119)

Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities

Background: Atopic dermatitis (AD) is known to be associated with other atopic comorbidities that all involve type 2 immune dysregulation. Tralokinumab is a monoclonal antibody that specifically targets interleukin-13.
Paller, Amy S., Geng, Bob, Thyssen, Jacob P., Boguniewicz, Mark, Soong, Weily, Schneider, Shannon, Wollenberg, Andreas, Bennike, Niels   +7 more
core   +1 more source

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

, 2019
Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects. This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled
Korn, Stephanie, Wang, Millie M., Kuna, Piotr, Cohen, David, Brusselle, Guy, Busse, William W, Busse, William, Magnan, Antoine, Piechowiak, Teresa, Bowen, Karin, Colice, Gene, Wang, Millie M   +11 more
core   +1 more source

Short-Term Cost per Responder of Lebrikizumab versus Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Model-Based Payer Analysis

ClinicoEconomics and Outcomes Research
Hamad AlmutlaqDepartment of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi ArabiaCorrespondence: Hamad Almutlaq, Department of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam ...
Almutlaq H
doaj  

Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational Study

Background: Biologic therapies such as dupilumab and tralokinumab have highly impacted on the management of moderate-to-severe atopic dermatitis (AD). However, recent clinical observations reported paradoxical adverse events (AEs), including psoriasis ...
Nettis, Eustachio, Schettini, Natale, Micali, Giuseppe, Napolitano, Maddalena, Tirone, Benedetta, Rubegni, Pietro, Guarneri, Fabrizio, Pezzolo, Elena, Sarno, Oriele, Potestio, Luca, Narcisi, Alessandra, Ippoliti, Elena, Carugno, Andrea, De Lucia, Mario, Morrone, Pietro, Rossi, Mariateresa, Satta, Rosanna, Lauletta, Giuseppe, Romanelli, Marco, Ribero, Simone, Guanti, Mario Bruno, Manzo Margiotta, Flavia, Peris, Ketty, Magnanimi, Lina Maria, Esposito, Maria, Ferrucci, Silvia Mariel, Piraccini, Bianca Maria, Hansel, Katharina, Gurioli, Carlotta, Pigliacelli, Flavia, Patruno, Cataldo, Lazzeri, Laura, Puca, Rosa Valentina, Mariano, Maria, Musumeci, Maria Letizia, Costanzo, Antonio, Barei, Francesca, Fargnoli, Maria Concetta, Zerbinati, Nicola, Stingeni, Luca, Cascio Ingurgio, Ruggero, Calabrese, Laura, Ortoncelli, Michela, Martina, Emanuela, Bonzano, Laura, Marasca, Claudio, Guglielmo, Alba, Antiga, Emiliano, Romita, Paolo, Gori, Niccolò, Trave, Ilaria, Grigolato, Laura, Foti, Caterina, Cataldo  Patruno, Mario Bruno , Puca Oriele , Martina Mario , Hansel Luca , Pezzolo Katharina , Mariano Flavia , Romita Benedetta , Lina Maria , Simone  Ribero, Maddalena  Napolitano, Alba Guglielmo, Rossi Caterina , Maria Concetta , Manzo Margiotta, Marco  Romanelli, Ruggero , Francesca  Barei, Luca  Potestio, Pietro  Morrone, Antonio  Costanzo, Bonzano Ilaria , Nettis Maria , Magnanimi Elena , Giuseppe  Lauletta, Andrea  Carugno, Peris Laura , Marasca, Fargnoli, Micali Emanuela , Bianca Maria , Maria Letizia , Gori Elena , Esposito, Sarno Claudio , Tirone Eustachio , Pietro  Rubegni, Gurioli Niccolò , De Lucia, Musumeci Giuseppe , Rosa Valentina , Trave, Satta Maria , Pigliacelli Flavia , Laura  Calabrese, Piraccini Carlotta , Laura  Lazzeri, Guanti, Michela  Ortoncelli, Grigolato Mariateresa , Stingeni Rosanna , Nicola  Zerbinati, Emiliano  Antiga, Fabrizio  Guarneri, Natale  Schettini, Ferrucci Laura , Ippoliti Ketty , Silvia Mariel , Foti Paolo , Alessandra  Narcisi, Cascio Ingurgio   +113 more
core   +1 more source

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study [PDF]

Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD).
Nettis, Eustachio, Napolitano, Maddalena, Tirone, Benedetta, Rubegni, Pietro, Guarneri, Fabrizio, Pezzolo, Elena, Ingurgio, Ruggero Cascio, Sarno, Oriele, Potestio, Luca, Narcisi, Alessandra, Ippoliti, Elena, Carugno, Andrea, Morrone, Pietro, Rossi, Mariateresa, Satta, Rosanna, Del Gaudio, Marika, Margiotta, Flavia Manzo, Romanelli, Marco, Ribero, Simone, Guanti, Mario Bruno, Peris, Ketty, Magnanimi, Lina Maria, Esposito, Maria, Ferrucci, Silvia Mariel, Piraccini, Bianca Maria, Hansel, Katharina, Gurioli, Carlotta, Pigliacelli, Flavia, Corazza, Monica, Patruno, Cataldo, Lazzeri, Laura, Puca, Rosa Valentina, Mariano, Maria, Rubegni, Giovanni, Costanzo, Antonio, Barei, Francesca, Fargnoli, Maria Concetta, Zerbinati, Nicola, di Vico, Francesca, Stingeni, Luca, Calabrese, Laura, Ortoncelli, Michela, Martina, Emanuela, Bonzano, Laura, Marasca, Claudio, Antiga, Emiliano, Romita, Paolo, Gori, Niccolò, Trave, Ilaria, Grigolato, Laura, Foti, Caterina, Barei F., Hansel K., Pezzolo E., Fargnoli M. C., Romanelli M., Romita P., Guanti M. B., Pigliacelli F., Rubegni P., Satta R., Tirone B., Gurioli C., Corazza M., Rossi M., Antiga E., Marasca C., Sarno O., Puca R. V., Bonzano L., Grigolato L., Magnanimi L. M., Ribero S., Margiotta F. M., di Vico F., Costanzo A., Ferrucci S. M., Napolitano M., Foti C., Rubegni G., Zerbinati N., Potestio L., Ingurgio R. C., Gori N., Patruno C., Peris K., Esposito M., Ortoncelli M., Mariano M., Ippoliti E., Martina E., Calabrese L., Piraccini B. M., Guarneri F., Stingeni L., Narcisi A., Lazzeri L., Del Gaudio M., Trave I., Morrone P., Carugno A., Nettis E.   +101 more
core   +1 more source

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2022
Eva Moennig, Stephan Traidl Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, GermanyCorrespondence: Eva Moennig, Division of Immunodermatology and Allergy Research ...
Moennig E, Traidl S
doaj  

Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16

Dermatology and Therapy
Introduction Investigator’s Global Assessment (IGA) of clear/almost clear (0/1) skin is a high standard to achieve after 16 weeks of treatment for patients with moderate-to-severe atopic dermatitis (AD) and does not capture clinically meaningful ...
Amy S. Paller, Andrew Blauvelt, Weily Soong, H. Chih-ho Hong, Marie L. A. Schuttelaar, Shannon K. R. Schneider, Eric L. Simpson   +6 more
doaj   +1 more source

Ocular abnormalities in patients with atopic dermatitis before and during treatment with dupilumab and tralokinumab

, 2023
Oogafwijkingen komen regelmatig voor bij patiënten met constitutioneel eczeem. Deze afwijkingen kunnen zowel veroorzaakt worden door de chronische inflammatie als door behandeling met dupilumab en tralokinumab, waarbij oogafwijkingen als bijwerking ...
de Bruin-Weller, M. S., de Boer, J. H., van Luijk, C. M., Achten, R. E., UMC Utrecht Holding, Infection & Immunity, MS Dermatologie/Allergologie, de Graaf, M., Dekkers, Coco C., Bakker, D. S., Other research (not in main researchprogram), MS Oogheelkunde, Unit Opleiding Dermatologie   +12 more
core  

Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Dermatology and Therapy
Introduction A systematic literature review and network meta-analysis (NMA) were conducted to compare the short-term efficacy of lebrikizumab to other biologic and Janus kinase (JAK) inhibitor monotherapies approved for moderate-to-severe atopic ...
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, Lisa Beck, Masahiro Kamata, Luis Puig, Marni Wiseman, Khaled Ezzedine, Alan D. Irvine, Peter Foley, James Del Rosso, Linda Stein Gold, Erin Johansson, Martin Dossenbach, Gaia Gallo, Buelent Akmaz, Marta Casillas, Andrei Karlsson, Tristan Curteis, Raj Chovatiya   +19 more
doaj   +1 more source

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring continuous therapy. The objective with the ECZTEND trial was to assess the long-term safety and efficacy of tralokinumab treatment.
Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich   +15 more
doaj   +1 more source